A randomised placebo-controlled crossover trial of micronised resveratrol as a treatment for Friedreich ataxia [ 2016 - 2020 ]

Research Grant

Researchers: Prof Martin Delatycki (Principal investigator) ,  A/Pr John O'Sullivan ,  A/Pr Noel Cranswick ,  A/Pr Paul Lockhart ,  Dr Eppie Yiu
View all 7 related researchers

Brief description Friedreich ataxia (FRDA) is the most common inherited cause of ataxia (incoordination). There are currently no treatments proven to slow or reverse its inexorable progression. We have shown that resveratrol holds promise as a treatment in an open-label study and now propose a placebo controlled study that will provide evidence of whether resveratrol can slow or reverse symptoms in this devastating disorder.

Funding Amount $AUD 559,828.67

Funding Scheme Project Grants

Notes Standard Project Grant